Article

Key clinical point: Premenopausal women with invasive lobular carcinoma (ILC) vs invasive ductal carcinoma (IDC) had better breast cancer-specific survival (BCSS) outcomes within 10 years after disease diagnosis, but the prognosis worsened in the long run.

Major finding: In the Surveillance, Epidemiology, and End Results (SEER) database, patients with ILC vs IDC showed improved BCSS outcomes during the first 10 years after diagnosis (hazard ratio [HR] 0.73; P < .001); however, after 10 years, the trend reversed and BCSS outcomes worsened by 80% in patients with ILC (HR 1.80; P < .001). ILC was also associated with worsened long-term prognosis in patients from the Korean Breast Cancer Registry and Asan Medical Center Research database.

Study details: This retrospective cohort study analyzed the data from three databases and included 225,938 premenopausal women (age < 50 years) with stages I-III ILC or IDC.

Disclosures: This study was supported by a grant from the Korea Health Technology R&D Project. O Metzger declared receiving grant funding and personal fees from various sources.

Source: Yoon TI et al. Survival outcomes in premenopausal patients with invasive lobular carcinoma. JAMA Netw Open. 2023;6(11):e2342270 (Nov 8). doi: 10.1001/jamanetworkopen.2023.42270

Key clinical point: Premenopausal women with invasive lobular carcinoma (ILC) vs invasive ductal carcinoma (IDC) had better breast cancer-specific survival (BCSS) outcomes within 10 years after disease diagnosis, but the prognosis worsened in the long run.

Major finding: In the Surveillance, Epidemiology, and End Results (SEER) database, patients with ILC vs IDC showed improved BCSS outcomes during the first 10 years after diagnosis (hazard ratio [HR] 0.73; P < .001); however, after 10 years, the trend reversed and BCSS outcomes worsened by 80% in patients with ILC (HR 1.80; P < .001). ILC was also associated with worsened long-term prognosis in patients from the Korean Breast Cancer Registry and Asan Medical Center Research database.

Study details: This retrospective cohort study analyzed the data from three databases and included 225,938 premenopausal women (age < 50 years) with stages I-III ILC or IDC.

Disclosures: This study was supported by a grant from the Korea Health Technology R&D Project. O Metzger declared receiving grant funding and personal fees from various sources.

Source: Yoon TI et al. Survival outcomes in premenopausal patients with invasive lobular carcinoma. JAMA Netw Open. 2023;6(11):e2342270 (Nov 8). doi: 10.1001/jamanetworkopen.2023.42270

Key clinical point: Premenopausal women with invasive lobular carcinoma (ILC) vs invasive ductal carcinoma (IDC) had better breast cancer-specific survival (BCSS) outcomes within 10 years after disease diagnosis, but the prognosis worsened in the long run.

Major finding: In the Surveillance, Epidemiology, and End Results (SEER) database, patients with ILC vs IDC showed improved BCSS outcomes during the first 10 years after diagnosis (hazard ratio [HR] 0.73; P < .001); however, after 10 years, the trend reversed and BCSS outcomes worsened by 80% in patients with ILC (HR 1.80; P < .001). ILC was also associated with worsened long-term prognosis in patients from the Korean Breast Cancer Registry and Asan Medical Center Research database.

Study details: This retrospective cohort study analyzed the data from three databases and included 225,938 premenopausal women (age < 50 years) with stages I-III ILC or IDC.

Disclosures: This study was supported by a grant from the Korea Health Technology R&D Project. O Metzger declared receiving grant funding and personal fees from various sources.

Source: Yoon TI et al. Survival outcomes in premenopausal patients with invasive lobular carcinoma. JAMA Netw Open. 2023;6(11):e2342270 (Nov 8). doi: 10.1001/jamanetworkopen.2023.42270

Key clinical point: Vaginal estrogen therapy did not worsen mortality outcomes in patients with breast cancer (BC) and genitourinary symptoms and can be considered if nonhormonal treatments prove unsuccessful.

Major finding: BC-specific mortality was not worsened in patients with BC who received vaginal estrogen therapy vs no hormone replacement therapy (hazard ratio 0.77; 95% CI 0.63-0.94).

Study details: Findings are from an analysis of two large cohorts including 49,237 females with BC, of which 5% of females used vaginal estrogen therapy after BC diagnosis.

Disclosures: This study was supported by grants from Cancer Research UK. Some authors declared receiving grants, personal fees, or nonfinancial support from and having other ties with several sources.

Source: McVicker L et al. Vaginal estrogen therapy use and survival in females with breast cancer. JAMA Oncol. 2023 (Nov 2). doi: 10.1001/jamaoncol.2023.4508

Key clinical point: Vaginal estrogen therapy did not worsen mortality outcomes in patients with breast cancer (BC) and genitourinary symptoms and can be considered if nonhormonal treatments prove unsuccessful.

Major finding: BC-specific mortality was not worsened in patients with BC who received vaginal estrogen therapy vs no hormone replacement therapy (hazard ratio 0.77; 95% CI 0.63-0.94).

Study details: Findings are from an analysis of two large cohorts including 49,237 females with BC, of which 5% of females used vaginal estrogen therapy after BC diagnosis.

Disclosures: This study was supported by grants from Cancer Research UK. Some authors declared receiving grants, personal fees, or nonfinancial support from and having other ties with several sources.

Source: McVicker L et al. Vaginal estrogen therapy use and survival in females with breast cancer. JAMA Oncol. 2023 (Nov 2). doi: 10.1001/jamaoncol.2023.4508

Key clinical point: Vaginal estrogen therapy did not worsen mortality outcomes in patients with breast cancer (BC) and genitourinary symptoms and can be considered if nonhormonal treatments prove unsuccessful.

Major finding: BC-specific mortality was not worsened in patients with BC who received vaginal estrogen therapy vs no hormone replacement therapy (hazard ratio 0.77; 95% CI 0.63-0.94).

Study details: Findings are from an analysis of two large cohorts including 49,237 females with BC, of which 5% of females used vaginal estrogen therapy after BC diagnosis.

Disclosures: This study was supported by grants from Cancer Research UK. Some authors declared receiving grants, personal fees, or nonfinancial support from and having other ties with several sources.

Source: McVicker L et al. Vaginal estrogen therapy use and survival in females with breast cancer. JAMA Oncol. 2023 (Nov 2). doi: 10.1001/jamaoncol.2023.4508

Key clinical point: Patients with moderate-to-severe atopic dermatitis (AD) presenting with classic or generalized lichenoid and inflammatory phenotypes vs other non-classic phenotypes and with Eczema Area and Severity Index (EASI) scores < 29 vs ≥ 29 showed an early response to dupilumab by achieving a mild disease state.

Major finding: Factors with a significant predictive value for an early response to dupilumab included the classic phenotype (odds ratio [OR] 6.92; 95% CI 2.04-23.48) or generalized lichenoid and inflammatory phenotypes (OR 4.22; 95% CI 1.22-14.66) vs the nummular eczema phenotype and a baseline EASI score of ≤ 24 (OR 3.13; 95% CI 1.81-5.41) or 24-29 (OR 1.79; 95% CI 1.05-3.07) vs ≥ 29.

Study details: Findings are from a retrospective single-center observational study including 492 patients (age > 12 years) with moderate-to-severe AD treated with dupilumab.

Disclosures: This study did not receive any external funding. S Ferrucci and AV Marzano declared serving as speakers or advisory board members of various organizations. The other authors declared no conflicts of interest.

Source: Ferrucci S et al. Predictive factors of early response to dupilumab in patients with moderate-to-severe atopic dermatitis. J Clin Med. 2023;12(20):6575 (Oct 17). doi: 10.3390/jcm12206575.

Key clinical point: Patients with moderate-to-severe atopic dermatitis (AD) presenting with classic or generalized lichenoid and inflammatory phenotypes vs other non-classic phenotypes and with Eczema Area and Severity Index (EASI) scores < 29 vs ≥ 29 showed an early response to dupilumab by achieving a mild disease state.

Major finding: Factors with a significant predictive value for an early response to dupilumab included the classic phenotype (odds ratio [OR] 6.92; 95% CI 2.04-23.48) or generalized lichenoid and inflammatory phenotypes (OR 4.22; 95% CI 1.22-14.66) vs the nummular eczema phenotype and a baseline EASI score of ≤ 24 (OR 3.13; 95% CI 1.81-5.41) or 24-29 (OR 1.79; 95% CI 1.05-3.07) vs ≥ 29.

Study details: Findings are from a retrospective single-center observational study including 492 patients (age > 12 years) with moderate-to-severe AD treated with dupilumab.

Disclosures: This study did not receive any external funding. S Ferrucci and AV Marzano declared serving as speakers or advisory board members of various organizations. The other authors declared no conflicts of interest.

Source: Ferrucci S et al. Predictive factors of early response to dupilumab in patients with moderate-to-severe atopic dermatitis. J Clin Med. 2023;12(20):6575 (Oct 17). doi: 10.3390/jcm12206575.

Key clinical point: Patients with moderate-to-severe atopic dermatitis (AD) presenting with classic or generalized lichenoid and inflammatory phenotypes vs other non-classic phenotypes and with Eczema Area and Severity Index (EASI) scores < 29 vs ≥ 29 showed an early response to dupilumab by achieving a mild disease state.

Major finding: Factors with a significant predictive value for an early response to dupilumab included the classic phenotype (odds ratio [OR] 6.92; 95% CI 2.04-23.48) or generalized lichenoid and inflammatory phenotypes (OR 4.22; 95% CI 1.22-14.66) vs the nummular eczema phenotype and a baseline EASI score of ≤ 24 (OR 3.13; 95% CI 1.81-5.41) or 24-29 (OR 1.79; 95% CI 1.05-3.07) vs ≥ 29.

Study details: Findings are from a retrospective single-center observational study including 492 patients (age > 12 years) with moderate-to-severe AD treated with dupilumab.

Disclosures: This study did not receive any external funding. S Ferrucci and AV Marzano declared serving as speakers or advisory board members of various organizations. The other authors declared no conflicts of interest.

Source: Ferrucci S et al. Predictive factors of early response to dupilumab in patients with moderate-to-severe atopic dermatitis. J Clin Med. 2023;12(20):6575 (Oct 17). doi: 10.3390/jcm12206575.

Key clinical point: Adults with moderate-to-severe atopic dermatitis (AD) are at a significantly higher risk for renal malignancy, with the risk for overall malignancy being higher in adults with AD regardless of the disease severity.

Major finding: Compared with adults without AD, those with moderate-to-severe AD had a significantly increased risk for renal malignancy (adjusted hazard ratio [aHR] 1.533; 95% CI 1.209-1.944); moreover, the risk for overall malignancy was higher in adults with mild (aHR 1.061; 95% CI 1.006-1.118) and moderate-to-severe (aHR 1.061; 95% CI 1.014-1.110) AD.

Study details: Findings are from a population-based cohort study including 22,430 adults with mild AD, 34,187 adults with moderate-to-severe AD, and 3,810,530 adults without AD.

Disclosures: This study did not receive any external funding. The authors declared no conflicts of interest.

Source: Oh J et al. Increased risk of renal malignancy in patients with moderate to severe atopic dermatitis. Cancers (Basel). 2023;15(20):5007 (Oct 16). doi: 10.3390/cancers15205007

Key clinical point: Adults with moderate-to-severe atopic dermatitis (AD) are at a significantly higher risk for renal malignancy, with the risk for overall malignancy being higher in adults with AD regardless of the disease severity.

Major finding: Compared with adults without AD, those with moderate-to-severe AD had a significantly increased risk for renal malignancy (adjusted hazard ratio [aHR] 1.533; 95% CI 1.209-1.944); moreover, the risk for overall malignancy was higher in adults with mild (aHR 1.061; 95% CI 1.006-1.118) and moderate-to-severe (aHR 1.061; 95% CI 1.014-1.110) AD.

Study details: Findings are from a population-based cohort study including 22,430 adults with mild AD, 34,187 adults with moderate-to-severe AD, and 3,810,530 adults without AD.

Disclosures: This study did not receive any external funding. The authors declared no conflicts of interest.

Source: Oh J et al. Increased risk of renal malignancy in patients with moderate to severe atopic dermatitis. Cancers (Basel). 2023;15(20):5007 (Oct 16). doi: 10.3390/cancers15205007

Key clinical point: Adults with moderate-to-severe atopic dermatitis (AD) are at a significantly higher risk for renal malignancy, with the risk for overall malignancy being higher in adults with AD regardless of the disease severity.

Major finding: Compared with adults without AD, those with moderate-to-severe AD had a significantly increased risk for renal malignancy (adjusted hazard ratio [aHR] 1.533; 95% CI 1.209-1.944); moreover, the risk for overall malignancy was higher in adults with mild (aHR 1.061; 95% CI 1.006-1.118) and moderate-to-severe (aHR 1.061; 95% CI 1.014-1.110) AD.

Study details: Findings are from a population-based cohort study including 22,430 adults with mild AD, 34,187 adults with moderate-to-severe AD, and 3,810,530 adults without AD.

Disclosures: This study did not receive any external funding. The authors declared no conflicts of interest.

Source: Oh J et al. Increased risk of renal malignancy in patients with moderate to severe atopic dermatitis. Cancers (Basel). 2023;15(20):5007 (Oct 16). doi: 10.3390/cancers15205007

Key clinical point: The binary outcomes of atopic dermatitis (AD) were most effectively improved up to week 16 by 30 mg upadacitinib daily and 200 mg abrocitinib daily, followed by 15 mg upadacitinib daily, and 600 mg dupilumab and subsequently 300 mg dupilumab every 2 weeks.

Major finding: The odds of achieving 50% improvement in the Eczema Area and Severity Index scores were higher with daily doses of 200 mg abrocitinib (odds ratio [OR] 1.5, 95% credible interval [CrI] 1.1-2.2), 30 mg upadacitinib (OR 2.5, 95% CrI 1.3-5.0), and 15 mg upadacitinib (OR 1.7; 95% CrI 0.9-3.3) and lower with 100 mg abrocitinib daily (OR 0.7; 95% CrI 0.5-1.0) and 4 mg baricitinib daily (OR 0.5; 95% CrI 0.3-0.7) compared with dupilumab every 2 weeks.

Study details: This network meta-analysis of 83 trials included 22,122 patients with moderate-to-severe AD receiving systemic immunomodulatory treatment for ≥8 weeks.

Disclosures: This study was sponsored by a UK National Institute for Health Research Career Development Fellowship held by C Flohr and other funds. Seven authors declared ties with various sources.

Source: Drucker AM et al. Comparing binary efficacy outcomes for systemic immunomodulatory treatments for atopic dermatitis in a living systematic review and network meta-analysis. Br J Dermatol. 2023 (Oct 13). doi: 10.1093/bjd/ljad393

Key clinical point: The binary outcomes of atopic dermatitis (AD) were most effectively improved up to week 16 by 30 mg upadacitinib daily and 200 mg abrocitinib daily, followed by 15 mg upadacitinib daily, and 600 mg dupilumab and subsequently 300 mg dupilumab every 2 weeks.

Major finding: The odds of achieving 50% improvement in the Eczema Area and Severity Index scores were higher with daily doses of 200 mg abrocitinib (odds ratio [OR] 1.5, 95% credible interval [CrI] 1.1-2.2), 30 mg upadacitinib (OR 2.5, 95% CrI 1.3-5.0), and 15 mg upadacitinib (OR 1.7; 95% CrI 0.9-3.3) and lower with 100 mg abrocitinib daily (OR 0.7; 95% CrI 0.5-1.0) and 4 mg baricitinib daily (OR 0.5; 95% CrI 0.3-0.7) compared with dupilumab every 2 weeks.

Study details: This network meta-analysis of 83 trials included 22,122 patients with moderate-to-severe AD receiving systemic immunomodulatory treatment for ≥8 weeks.

Disclosures: This study was sponsored by a UK National Institute for Health Research Career Development Fellowship held by C Flohr and other funds. Seven authors declared ties with various sources.

Source: Drucker AM et al. Comparing binary efficacy outcomes for systemic immunomodulatory treatments for atopic dermatitis in a living systematic review and network meta-analysis. Br J Dermatol. 2023 (Oct 13). doi: 10.1093/bjd/ljad393

Key clinical point: The binary outcomes of atopic dermatitis (AD) were most effectively improved up to week 16 by 30 mg upadacitinib daily and 200 mg abrocitinib daily, followed by 15 mg upadacitinib daily, and 600 mg dupilumab and subsequently 300 mg dupilumab every 2 weeks.

Major finding: The odds of achieving 50% improvement in the Eczema Area and Severity Index scores were higher with daily doses of 200 mg abrocitinib (odds ratio [OR] 1.5, 95% credible interval [CrI] 1.1-2.2), 30 mg upadacitinib (OR 2.5, 95% CrI 1.3-5.0), and 15 mg upadacitinib (OR 1.7; 95% CrI 0.9-3.3) and lower with 100 mg abrocitinib daily (OR 0.7; 95% CrI 0.5-1.0) and 4 mg baricitinib daily (OR 0.5; 95% CrI 0.3-0.7) compared with dupilumab every 2 weeks.

Study details: This network meta-analysis of 83 trials included 22,122 patients with moderate-to-severe AD receiving systemic immunomodulatory treatment for ≥8 weeks.

Disclosures: This study was sponsored by a UK National Institute for Health Research Career Development Fellowship held by C Flohr and other funds. Seven authors declared ties with various sources.

Source: Drucker AM et al. Comparing binary efficacy outcomes for systemic immunomodulatory treatments for atopic dermatitis in a living systematic review and network meta-analysis. Br J Dermatol. 2023 (Oct 13). doi: 10.1093/bjd/ljad393

Key clinical point: Atopic dermatitis (AD) significantly increases the risk for cognitive dysfunction, particularly that of all-cause dementia and Alzheimer’s disease-related dementia, in middle-aged adults (age 45-59 years) and older adults (age ≥60 years).

Major finding: Patients with AD vs control individuals had a significantly higher risk of developing all-cause dementia (pooled hazard ratio [HR] 1.16; 95% CI 1.10-1.23) and Alzheimer’s disease-related dementia (pooled HR 1.28; 95% CI 1.01-1.63). However, no significant association was observed between AD and vascular dementia (pooled HR 1.42; 95% CI 0.99-2.04).

Study details: Findings are from a meta-analysis of five studies including 8,595,252 patients with AD and a corresponding number of control individuals without AD.

Disclosures: This study did not receive any specific funding. The authors declared no conflicts of interest.

Source: Zhou Q et al. Atopic dermatitis and cognitive dysfunction in middle-aged and older adults: A systematic review and meta-analysis. PLoS One. 2023;18(10):e0292987 (Oct 25). doi: 10.1371/journal.pone.0292987

Key clinical point: Atopic dermatitis (AD) significantly increases the risk for cognitive dysfunction, particularly that of all-cause dementia and Alzheimer’s disease-related dementia, in middle-aged adults (age 45-59 years) and older adults (age ≥60 years).

Major finding: Patients with AD vs control individuals had a significantly higher risk of developing all-cause dementia (pooled hazard ratio [HR] 1.16; 95% CI 1.10-1.23) and Alzheimer’s disease-related dementia (pooled HR 1.28; 95% CI 1.01-1.63). However, no significant association was observed between AD and vascular dementia (pooled HR 1.42; 95% CI 0.99-2.04).

Study details: Findings are from a meta-analysis of five studies including 8,595,252 patients with AD and a corresponding number of control individuals without AD.

Disclosures: This study did not receive any specific funding. The authors declared no conflicts of interest.

Source: Zhou Q et al. Atopic dermatitis and cognitive dysfunction in middle-aged and older adults: A systematic review and meta-analysis. PLoS One. 2023;18(10):e0292987 (Oct 25). doi: 10.1371/journal.pone.0292987

Key clinical point: Atopic dermatitis (AD) significantly increases the risk for cognitive dysfunction, particularly that of all-cause dementia and Alzheimer’s disease-related dementia, in middle-aged adults (age 45-59 years) and older adults (age ≥60 years).

Major finding: Patients with AD vs control individuals had a significantly higher risk of developing all-cause dementia (pooled hazard ratio [HR] 1.16; 95% CI 1.10-1.23) and Alzheimer’s disease-related dementia (pooled HR 1.28; 95% CI 1.01-1.63). However, no significant association was observed between AD and vascular dementia (pooled HR 1.42; 95% CI 0.99-2.04).

Study details: Findings are from a meta-analysis of five studies including 8,595,252 patients with AD and a corresponding number of control individuals without AD.

Disclosures: This study did not receive any specific funding. The authors declared no conflicts of interest.

Source: Zhou Q et al. Atopic dermatitis and cognitive dysfunction in middle-aged and older adults: A systematic review and meta-analysis. PLoS One. 2023;18(10):e0292987 (Oct 25). doi: 10.1371/journal.pone.0292987

Key clinical point: Children with atopic dermatitis (AD) have an increased risk for multiple comorbidities, even beyond atopic disorders, with a positive association between AD severity and the risk for comorbidity onset.

Major finding: In children with vs without AD, the risk for hypersensitivity and allergic disorders was the highest (hazard ratio [HR] 3.87; 95% CI 3.77-3.97), followed by that for malignancies (HR 2.53; 95% CI 1.96-3.26) and immunological and inflammatory disorders (HR 2.36; 95% CI 2.22-2.50). Hypersensitivity onset risk increased in children with mild-to-moderate (adjusted HR 2.71; 95% CI 2.41-3.05) and severe (adjusted HR 3.56; 95% CI 3.10-4.09) AD compared with those in remission.

Study details: This observational, retrospective cohort study included 165,145 children with AD (age < 18 years) who were matched with 165,145 children without AD.

Disclosures: This study was sponsored by Pfizer Inc. Some authors declared receiving research grants or consultancy fees from or serving as advisors, investigators, etc., for Pfizer and others. Six authors declared being employees of or holding stock or stock options in Pfizer.

Source: von Kobyletzki L et al. Comorbidities in childhood atopic dermatitis: A population-based study. J Eur Acad Dermatol Venereol. 2023 (Oct 12). doi: 10.1111/jdv.19569

Key clinical point: Children with atopic dermatitis (AD) have an increased risk for multiple comorbidities, even beyond atopic disorders, with a positive association between AD severity and the risk for comorbidity onset.

Major finding: In children with vs without AD, the risk for hypersensitivity and allergic disorders was the highest (hazard ratio [HR] 3.87; 95% CI 3.77-3.97), followed by that for malignancies (HR 2.53; 95% CI 1.96-3.26) and immunological and inflammatory disorders (HR 2.36; 95% CI 2.22-2.50). Hypersensitivity onset risk increased in children with mild-to-moderate (adjusted HR 2.71; 95% CI 2.41-3.05) and severe (adjusted HR 3.56; 95% CI 3.10-4.09) AD compared with those in remission.

Study details: This observational, retrospective cohort study included 165,145 children with AD (age < 18 years) who were matched with 165,145 children without AD.

Disclosures: This study was sponsored by Pfizer Inc. Some authors declared receiving research grants or consultancy fees from or serving as advisors, investigators, etc., for Pfizer and others. Six authors declared being employees of or holding stock or stock options in Pfizer.

Source: von Kobyletzki L et al. Comorbidities in childhood atopic dermatitis: A population-based study. J Eur Acad Dermatol Venereol. 2023 (Oct 12). doi: 10.1111/jdv.19569

Key clinical point: Children with atopic dermatitis (AD) have an increased risk for multiple comorbidities, even beyond atopic disorders, with a positive association between AD severity and the risk for comorbidity onset.

Major finding: In children with vs without AD, the risk for hypersensitivity and allergic disorders was the highest (hazard ratio [HR] 3.87; 95% CI 3.77-3.97), followed by that for malignancies (HR 2.53; 95% CI 1.96-3.26) and immunological and inflammatory disorders (HR 2.36; 95% CI 2.22-2.50). Hypersensitivity onset risk increased in children with mild-to-moderate (adjusted HR 2.71; 95% CI 2.41-3.05) and severe (adjusted HR 3.56; 95% CI 3.10-4.09) AD compared with those in remission.

Study details: This observational, retrospective cohort study included 165,145 children with AD (age < 18 years) who were matched with 165,145 children without AD.

Disclosures: This study was sponsored by Pfizer Inc. Some authors declared receiving research grants or consultancy fees from or serving as advisors, investigators, etc., for Pfizer and others. Six authors declared being employees of or holding stock or stock options in Pfizer.

Source: von Kobyletzki L et al. Comorbidities in childhood atopic dermatitis: A population-based study. J Eur Acad Dermatol Venereol. 2023 (Oct 12). doi: 10.1111/jdv.19569

Key clinical point: Compared with dupilumab, lebrikizumab in less frequent doses shows equal or improved long-term maintenance of efficacy and overall adverse event rates in patients with moderate-to-severe atopic dermatitis (AD).

Major finding: Between weeks 16 and 52, patients receiving lebrikizumab every 4 weeks (Q4W) vs dupilumab weekly or biweekly (QW/Q2W) were more likely to maintain Investigator’s Global Assessment scores of 0 or 1 (risk ratio [RR] 1.334; P  =  .035). Lebrikizumab and dupilumab were comparable in terms of adverse event rates (RR 1.052; P  =  .526) and maintenance of 75% improvement in Eczema Area and Severity Index scores (RR 0.937; P  =  .490).

Study details: This matching-adjusted indirect comparison study analyzed the data of adult patients with moderate-to-severe AD who received lebrikizumab Q4W (n = 101) in ADvocate1 and ADvocate2 or dupilumab QW/Q2W (n = 169) in SOLO-CONTINUE and achieved a treatment response at week 16.

Disclosures: This study was funded by Almirall S.A., Spain. Two authors declared being employees of Almirall S.A. The other authors declared ties with various sources, including Almirall.

Source: Rand K et al. Matching-adjusted indirect comparison of the long-term efficacy maintenance and adverse event rates of lebrikizumab versus dupilumab in moderate-to-severe atopic dermatitis. Dermatol Ther (Heidelb). 2023 (Oct 28). doi: 10.1007/s13555-023-01058-z

Key clinical point: Compared with dupilumab, lebrikizumab in less frequent doses shows equal or improved long-term maintenance of efficacy and overall adverse event rates in patients with moderate-to-severe atopic dermatitis (AD).

Major finding: Between weeks 16 and 52, patients receiving lebrikizumab every 4 weeks (Q4W) vs dupilumab weekly or biweekly (QW/Q2W) were more likely to maintain Investigator’s Global Assessment scores of 0 or 1 (risk ratio [RR] 1.334; P  =  .035). Lebrikizumab and dupilumab were comparable in terms of adverse event rates (RR 1.052; P  =  .526) and maintenance of 75% improvement in Eczema Area and Severity Index scores (RR 0.937; P  =  .490).

Study details: This matching-adjusted indirect comparison study analyzed the data of adult patients with moderate-to-severe AD who received lebrikizumab Q4W (n = 101) in ADvocate1 and ADvocate2 or dupilumab QW/Q2W (n = 169) in SOLO-CONTINUE and achieved a treatment response at week 16.

Disclosures: This study was funded by Almirall S.A., Spain. Two authors declared being employees of Almirall S.A. The other authors declared ties with various sources, including Almirall.

Source: Rand K et al. Matching-adjusted indirect comparison of the long-term efficacy maintenance and adverse event rates of lebrikizumab versus dupilumab in moderate-to-severe atopic dermatitis. Dermatol Ther (Heidelb). 2023 (Oct 28). doi: 10.1007/s13555-023-01058-z

Key clinical point: Compared with dupilumab, lebrikizumab in less frequent doses shows equal or improved long-term maintenance of efficacy and overall adverse event rates in patients with moderate-to-severe atopic dermatitis (AD).

Major finding: Between weeks 16 and 52, patients receiving lebrikizumab every 4 weeks (Q4W) vs dupilumab weekly or biweekly (QW/Q2W) were more likely to maintain Investigator’s Global Assessment scores of 0 or 1 (risk ratio [RR] 1.334; P  =  .035). Lebrikizumab and dupilumab were comparable in terms of adverse event rates (RR 1.052; P  =  .526) and maintenance of 75% improvement in Eczema Area and Severity Index scores (RR 0.937; P  =  .490).

Study details: This matching-adjusted indirect comparison study analyzed the data of adult patients with moderate-to-severe AD who received lebrikizumab Q4W (n = 101) in ADvocate1 and ADvocate2 or dupilumab QW/Q2W (n = 169) in SOLO-CONTINUE and achieved a treatment response at week 16.

Disclosures: This study was funded by Almirall S.A., Spain. Two authors declared being employees of Almirall S.A. The other authors declared ties with various sources, including Almirall.

Source: Rand K et al. Matching-adjusted indirect comparison of the long-term efficacy maintenance and adverse event rates of lebrikizumab versus dupilumab in moderate-to-severe atopic dermatitis. Dermatol Ther (Heidelb). 2023 (Oct 28). doi: 10.1007/s13555-023-01058-z

Key clinical point: Patients with alopecia areata (AA) have an increased risk for atopic dermatitis (AD) and vice versa.

Major finding: Patients with AA vs control individuals had a significantly higher risk of developing AD (adjusted odds ratio [aOR] 4.42; P < .001). Reciprocally, patients with AD vs control individuals also had a significantly higher risk of developing AA (aOR 5.08; P < .001).

Study details: Findings are from a nested case-control study including 984 patients with AA from the All of Us database (USA), who were matched with 3936 control individuals without AA using nearest neighbor propensity-score matching.

Disclosures: This study did not disclose any funding source. E Guttman-Yassky and B Ungar declared receiving institutional grants from, serving as consultants for, or having other ties with various sources. The other authors declared no conflicts of interest.

Source: Diaz MJ et al. Association between alopecia areata and atopic dermatitis: A nested case-control study of the All of Us database. J Am Acad Dermatol. 2023 (Oct 21). doi: 10.1016/j.jaad.2023.10.031

Key clinical point: Patients with alopecia areata (AA) have an increased risk for atopic dermatitis (AD) and vice versa.

Major finding: Patients with AA vs control individuals had a significantly higher risk of developing AD (adjusted odds ratio [aOR] 4.42; P < .001). Reciprocally, patients with AD vs control individuals also had a significantly higher risk of developing AA (aOR 5.08; P < .001).

Study details: Findings are from a nested case-control study including 984 patients with AA from the All of Us database (USA), who were matched with 3936 control individuals without AA using nearest neighbor propensity-score matching.

Disclosures: This study did not disclose any funding source. E Guttman-Yassky and B Ungar declared receiving institutional grants from, serving as consultants for, or having other ties with various sources. The other authors declared no conflicts of interest.

Source: Diaz MJ et al. Association between alopecia areata and atopic dermatitis: A nested case-control study of the All of Us database. J Am Acad Dermatol. 2023 (Oct 21). doi: 10.1016/j.jaad.2023.10.031

Key clinical point: Patients with alopecia areata (AA) have an increased risk for atopic dermatitis (AD) and vice versa.

Major finding: Patients with AA vs control individuals had a significantly higher risk of developing AD (adjusted odds ratio [aOR] 4.42; P < .001). Reciprocally, patients with AD vs control individuals also had a significantly higher risk of developing AA (aOR 5.08; P < .001).

Study details: Findings are from a nested case-control study including 984 patients with AA from the All of Us database (USA), who were matched with 3936 control individuals without AA using nearest neighbor propensity-score matching.

Disclosures: This study did not disclose any funding source. E Guttman-Yassky and B Ungar declared receiving institutional grants from, serving as consultants for, or having other ties with various sources. The other authors declared no conflicts of interest.

Source: Diaz MJ et al. Association between alopecia areata and atopic dermatitis: A nested case-control study of the All of Us database. J Am Acad Dermatol. 2023 (Oct 21). doi: 10.1016/j.jaad.2023.10.031

Key clinical point: In real-world settings, dupilumab is safe and effective in children with moderate-to-severe atopic dermatitis (AD) who are age > 2 to < 12 years.

Major finding: Dupilumab led to significant improvements in the Eczema Area and Severity Index scores and Body Surface Area scores in children age > 2 to < 6 years (both P < .001) and ≥ 6 to < 12 years (both P < .001) but not in those age ≤ 2 years (P  =  .191 and P  =  .092, respectively). No serious adverse events were reported.

Study details: This multicenter retrospective study included 63 children with moderate-to-severe AD who were classified relative to age: ≤ 2 years (n = 4), > 2 to < 6 years (n = 25), and ≥ 6 to < 12 years (n = 34), with most having received prior systemic immunosuppressive therapies and all being treated with dupilumab.

Disclosures: This study did not disclose any funding source. Several authors declared receiving grants or honoraria from or serving as investigators, advisors, consultants, or speakers for various sources.

Source: Martinez-Cabriales S et al. Multicenter Canadian case series of pediatric patients less than 12 years of age with moderate-to-severe atopic dermatitis treated with dupilumab. Pediatr Dermatol. 2023 (Oct 31). doi: 10.1111/pde.15418

Key clinical point: In real-world settings, dupilumab is safe and effective in children with moderate-to-severe atopic dermatitis (AD) who are age > 2 to < 12 years.

Major finding: Dupilumab led to significant improvements in the Eczema Area and Severity Index scores and Body Surface Area scores in children age > 2 to < 6 years (both P < .001) and ≥ 6 to < 12 years (both P < .001) but not in those age ≤ 2 years (P  =  .191 and P  =  .092, respectively). No serious adverse events were reported.

Study details: This multicenter retrospective study included 63 children with moderate-to-severe AD who were classified relative to age: ≤ 2 years (n = 4), > 2 to < 6 years (n = 25), and ≥ 6 to < 12 years (n = 34), with most having received prior systemic immunosuppressive therapies and all being treated with dupilumab.

Disclosures: This study did not disclose any funding source. Several authors declared receiving grants or honoraria from or serving as investigators, advisors, consultants, or speakers for various sources.

Source: Martinez-Cabriales S et al. Multicenter Canadian case series of pediatric patients less than 12 years of age with moderate-to-severe atopic dermatitis treated with dupilumab. Pediatr Dermatol. 2023 (Oct 31). doi: 10.1111/pde.15418

Key clinical point: In real-world settings, dupilumab is safe and effective in children with moderate-to-severe atopic dermatitis (AD) who are age > 2 to < 12 years.

Major finding: Dupilumab led to significant improvements in the Eczema Area and Severity Index scores and Body Surface Area scores in children age > 2 to < 6 years (both P < .001) and ≥ 6 to < 12 years (both P < .001) but not in those age ≤ 2 years (P  =  .191 and P  =  .092, respectively). No serious adverse events were reported.

Study details: This multicenter retrospective study included 63 children with moderate-to-severe AD who were classified relative to age: ≤ 2 years (n = 4), > 2 to < 6 years (n = 25), and ≥ 6 to < 12 years (n = 34), with most having received prior systemic immunosuppressive therapies and all being treated with dupilumab.

Disclosures: This study did not disclose any funding source. Several authors declared receiving grants or honoraria from or serving as investigators, advisors, consultants, or speakers for various sources.

Source: Martinez-Cabriales S et al. Multicenter Canadian case series of pediatric patients less than 12 years of age with moderate-to-severe atopic dermatitis treated with dupilumab. Pediatr Dermatol. 2023 (Oct 31). doi: 10.1111/pde.15418